Spray Drying of Amifostine

Amifostine is a cytoprotective agent used to reduce side effects of cancer therapies. Spray drying enables the production of stable, patient-friendly powders with optimized particle properties and bioavailability. It supports oral formulations with controlled release for improved therapeutic outcomes. Application Note No. 427 provides starting parameters, formulations, and results, including Amifostine/PLGA concentrations and solvent systems.

Amifostine/PLGAのサンプル濃度（0.4:1.0および1:1）、Amifostine（400mg/1mlまたは1000 mg/2ml）を電解水中に溶解し、1 gのPLGAを含む50mLのジクロロメタン中に乳化させます。水中のAmifostine溶媒、DCMキャリア中のPLGA、フィルモジェンポリ（DL-乳酸–グリコール酸）PLGA 50:50（RG 502、固有粘度0.2 dL/g）、ホスファチジルコリン（界面活性剤）。